Indications for: SKYRIZI

Moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy.

Adult Dosage:

Administer by SC inj into abdomen, thighs (or may be given by healthcare provider only in upper, outer arm). ≥18yrs: 150mg by SC inj at Week 0, Week 4, and every 12 weeks thereafter.

Children Dosage:

<18yrs: not established.

SKYRIZI Warnings/Precautions:

Use under physician supervision and guidance. May increase risk of infections. Chronic or history of recurrent infection. Evaluate for tuberculosis (TB) infection prior to initiation. History of latent or active TB (without confirmed adequate treatment); consider anti-TB therapy prior to initiation. Monitor for signs/symptoms of active TB during and after therapy. Patients with active TB infection: do not initiate. Complete all age appropriate immunizations according to current guidelines prior to initiating therapy. Pregnancy. Nursing mothers.

SKYRIZI Classification:

Interleukin-23 antagonist.

SKYRIZI Interactions:

Avoid use of live vaccines.

Adverse Reactions:

Upper respiratory infections, headache, fatigue, inj site reactions, tinea infections.

Generic Drug Availability:


How Supplied:

Single-dose prefilled syringe (75mg/0.83mL)—2 (w. supplies); Single-dose prefilled pen or syringe (150mg/mL)—1 (w. supplies)

Pricing for SKYRIZI

1 pen of 150mg/ml package (Qty: 1)
Appx. price $16986